FORM D

UNITED STATES FEB 2 3 2004
SECURITIES AND EXCHANGE COMMISSION

04008780

OMB NUMBER:

DE

May 30, 2005

Expires: Estimated average burden

ON.

hours per response......1.00

Washington, D.C. 20549 FORM D

NOTICE OF SALE OF SECURITIES PURSUÂNT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

	SEC USE ONLY
Prefix	Serial
	DATE RECEIVED

INTEODALI IMPED OPERDINO EVENDENIAN	l l		
UNIFORM LIMITED OFFERING EXEMPTION	DATE RECEIVED		
Name of Offering (□ check if this is an amendment and name has changed, and indicate change.) Common Stock	1115285		
Filing Under (Check box(es) that apply): □ Rule 504 □ Rule 505 ■ Rule 506 □ Section Type of Filing: ■ New Filing □ Amendment	1 4(6) □ ULOE		
A. BASIC IDENTIFICATION DAT	A		
Enter the information requested about the issuer			
Name of Issuer (□ check if this is an amendment and name has changed, and indicate change.)			
Eyetech Pharmaceuticals, Inc.			
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)		
500 Seventh Avenue, 18th Floor, New York, NY 10018	212-997-9241		
Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices)	Telephone Number (Including Area Code)		
Brief Description of Business:			
A biopharmaceutical company formed to discover, develop and commercialize new drugs to reduce	e and prevent vision loss		
Type of Business Organization			
■ corporation ☐ limited partnership, already formed	other (please specify): FEB 24. 2004		
□ business trust □ limited partnership, to be formed			
Month Year Actual or Estimated Date of Incorporation or Organization 02 00 ■ Actual □ Estimated Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State	THOMSON FINANCIAL		

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

CN for Canada; FN for other foreign jurisdiction)

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

	$r_{\rm TE}$	A TITE	\mathbf{r}	n i
A	C C PC	V 1	ĸı	í٧

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

N

A. BASIC IDENTIFICATION DATA						
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 						
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Guyer, David R.						
Business or Residence Address	(Number and S	treet, City, State, Zip Co	de)			
		•				
c/o Eyetech Pharmaceuticals, Inc., 500 S						
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	■ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Sblendorio, Glenn						
Business or Residence Address	(Number and S	treet, City, State, Zip Co	de)			
c/o Eyetech Pharmaceuticals, Inc., 500 S	Savanth Avanua	18th Floor New York	NV 10018			
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)	Li Homoter	Delicitetat Owlier	- Laceutive Officer	- Director	Ocheral and/of Wanaging Lariner	
,						
Adamis, Anthony P.	01 1 10	- C': C: - T' - C				
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	ie)			
c/o Eyetech Pharmaceuticals, Inc., 500 S	Seventh Avenue	, 18th Floor, New York,	NY 10018			
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
McLaughlin, John						
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	le)			
c/o Eyetech Pharmaceuticals, Inc., 500 S Check Box(es) that Apply:						
Full Name (Last name first, if individual)	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
run Name (Last name mst, ii individuat)		•				
Akkaraju, Srinivas		 				
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)			
c/o Eyetech Pharmaceuticals, Inc., 500 S	Seventh Avenue	. 18th Floor, New York.	NY 10018			
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Gu						
Glick, Martin Business or Residence Address	(Number and S	treet, City, State, Zip Co	de)			
		· -				
c/o Eyetech Pharmaceuticals, Inc., 500 S	Seventh Avenue	, 18th Floor, New York,	NY 10018			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual)						
Mullen, Michael						
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)			
c/o Eyetech Pharmaceuticals, Inc., 500 Seventh Avenue, 18th Floor, New York, NY 10018						
Check Box(es) that Apply:		, 18 th Floor, New York, Beneficial Owner		= Diseases	Company and (on Managing Posts	
Full Name (Last name first, if individual)	□ Promoter	in Denencial Owner	□ Executive Officer	■ Director	☐ General and/or Managing Partner	
Ton Manie (Last name mst, it muryidual)						
Patel, Samir						
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)			
c/o Evetech Pharmaceuticals, Inc., 500 S	Seventh Avenue	18th Floor New York	NV 10018			

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

A. BASIC IDENTIFICATION DATA Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Check Box(es) that Apply: □ Promoter ☐ Beneficial Owner □ Executive Officer ■ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Penhoet, Ed Business or Residence Address (Number and Street, City, State, Zip Code) c/o Eyetech Pharmaceuticals, Inc., 500 Seventh Avenue, 18th Floor, New York, NY 10018 Check Box(es) that Apply: □ Promoter ☐ Beneficial Owner □ Executive Officer ■ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Simon, Henry **Business or Residence Address** (Number and Street, City, State, Zip Code) c/o Evetech Pharmaceuticals, Inc., 500 Seventh Avenue, 18th Floor, New York, NY 10018 Check Box(es) that Apply: ☐ Promoter ■ Beneficial Owner ☐ Executive Officer ■ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Wicker, Damion E. **Business or Residence Address** (Number and Street, City, State, Zip Code) c/o Eyetech Pharmaceuticals, Inc., 500 Seventh Avenue, 18th Floor, New York, NY 10018 Check Box(es) that Apply: □ Beneficial Owner ■ Executive Officer ☐ General and/or Managing Partner ☐ Promoter □ Director Full Name (Last name first, if individual) Chaney, Paul G. **Business or Residence Address** (Number and Street, City, State, Zip Code) c/o Eyetech Pharmaceuticals, Inc., 500 Seventh Avenue, 18th Floor, New York, NY 10018 Check Box(es) that Apply: □ Promoter □ Beneficial Owner ■ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Altschuler, Douglas H. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Eyetech Pharmaceuticals, Inc., 500 Seventh Avenue, 18th Floor, New York, NY 10018 Check Box(es) that Apply: ☐ Executive Officer □ Promoter ■ Beneficial Owner □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) J.P. Morgan Partners (BHCA), L.P. Business or Residence Address (Number and Street, City, State, Zip Code) One Bush Street, San Francisco, CA 94104 Check Box(es) that Apply: ☐ General and/or Managing Partner □ Promoter ☐ Beneficial Owner □ Executive Officer □ Director Full Name (Last name first, if individual) **Business or Residence Address** (Number and Street, City, State, Zip Code) Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ General and/or Managing Partner □ Director Full Name (Last name first, if individual) **Business or Residence Address** (Number and Street, City, State, Zip Code) Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code)

B. INFORMATION ABOUT OFFERING						
				No		
1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?						
2.	Answer also in Appendix, Column 2, if filing under ULOE. 2. What is the minimum investment that will be accepted from any individual?					
		`	<u>N/A</u> Yes	No		
3.	Does the offering permit joint ownership of a single unit?					
4.						
Full	Name (Last name first, if individual)					
Non						
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)					
Nor	ne of Associated Broker or Dealer					
Ivaii	ic of Associated Diokel of Deater					
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers					
	(· · · · · · · · · · · · · · · · · · ·	All S	tates			
~ () ~ ()	AL] _ [AK] _ [AZ] _ [AR] _ [CA] _ [CO] _ [CT] _ [DE] _ [DC] _ [FL] _ [GA] IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK] RI] _ [SC] _ [SD] _ [TN] _ [TX] _ [UT] _ [VT] _ [VA] _ [WA] _ [WV] _ [WI]	1] _ [A] _ [O] _ [V] _	(S) (R)	_ [ID] _ [MO] _ [PA] _ [PR]		
Full	name (Last name first, if individual)		- ' -			
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)					
Nam	ne of Associated Broker or Dealer					
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers					
	(Check "All States" or check individual States)	All S	tates			
] _] _] _	MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK] RI] _ [SC] _ [SD] _ [TN] _ [TX] _ [UT] _ [VT] _ [VA] _ [WA] _ [WV] _ [WI]	- [N - [N - [V	AS] DR]	_ [ID] _ [MO] _ [PA] _ [PR]		
Full	Name (Last name first, if individual)					
Business or Residence Address (Number and Street, City, State, Zip Code)						
Name of Associated Broker or Dealer						
States in which Person Listed Has Solicited or Intends to Solicit Purchasers						
(Check "All States" or check individual States)						
_ [_ [AL] _ [AK] _ [AZ] _ [AR] _ [CA] _ [CO] _ [CT] _ [DE] _ [DC] _ [FL] _ [GA] [IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK] [RI] _ [SC] _ [SD] _ [TN] _ [TX] _ [TX] _ [VT] _ [VA] _ [WA] _ [WV] _ [WI]	- [N - [N - [V] - [V]	AS] DR]	_ [ID] _ [MO] _ [PA] _ [PR]		

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box pand indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	\$	\$
	Equity	\$ <u>9,999,990</u>	\$ <u>9,999,990</u>
	■ Common □ Preferred		
	Convertible Securities (including warrants)	\$	\$
	Partnership Interests	\$	\$
	Other (Specify)	\$	\$
	Total	\$ 9,999,990	\$ <u>9,999,990</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	1	\$ <u>9,999,990</u>
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE		Ψ
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1. Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		\$
	Regulation A		\$
	Rule 504		\$
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$
	Printing and Engraving Costs	۵	\$
	Legal Fees		\$ <u>5,000</u>
	Accounting Fees	۵	\$
	Engineering Fees		\$
	Sales Commissions (specify finders' fees separately)		\$
	Other Expenses (identify)		\$
	Total		\$5,000

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

b. Enter the difference between the aggrega 1 and total expenses furnished in response to "adjusted gross proceeds to the issuer."	Part C - Question 4.a. This difference is	C – Question s the		\$ <u>9.994.990</u>
Indicate below the amount of the adjusted g for each of the purposes shown. If the amou and check the box to the left of the estimate adjusted gross proceeds to the issuer set for	Int for any purpose is not known; furnish the total of the payments listed must eq	ual the		
			Payments to Officers; Directors, & Affiliates	Payments:To Others
Salaries and fees		•	S	(D) (S) (S) (S) (S) (S) (S) (S) (S) (S) (S
Purchase of real estate		•	\$ <u>-</u>	
Purchase, rental or leasing and installation	alia i Mara da ilika bata manda kilo ya kalifitti da		\$	o Soldiani
Construction or leasing of plant buildings a	. Prije i projektivanski projektiva i projektiva i dela 1			S
Acquisition of other business (including th	e value of securities involved in this offer	ng		
that may be used in exchange for the assets merger)	or securities of another issuer pursuant to		\$	Ö
Repayment of indebtedness	경영 영화 회의 교육적 한 위 경우학교원 교육의 기원에 가입니다는 전 문항에서 되었다. 보험 보호를		S	G (2) 3 (2) (3)
Working capital and product development	마기 때 마음을 잃어놓았다. 하늘하는 나는 그로 화가 없다고요.		S	S 9,994,990
Other (specify):		o d	s	.
				
1.4		Žistorijas	S	\$ 9,994,990
Total Payments Listed (column totals add			■ \$ <u>9.9</u> 9	4.990
A CONTRACTOR OF THE CONTRACTOR				
	D. FEDERAL SIG	NATURE		
The issuer has duly caused this notice to be sig	ned by the undersigned duly authorized pe	rson. If this notice	e is filed under Rule 505, the fo	ollowing signature constitutes
The issuer has duly caused this notice to be sig an undertaking by the issuer to furnish to the U non-accredited investor pursuant to paragraph (.5. Securides and exchange Continussion,	upon writen requ		
Issuer (Print of Type)	÷«, ≓ Signatúre · · · ·		Date	
Eyetech Pharmaceuticals, Inc.		. N = N	February 18	, 2004
	Title of Signet (Print or Type)		Suntal Will	
Name of Signer (Print or Type) Glenn P. Sblendorio	Chief Financial Officer and S	enior Vice Presid	ent, Finance	
Gener. Solelido 10				
		7 (12) 2 (1)		
				New Art State Control
			76.7	
	ATTENTION ts or omissions of fact constitut	a fodgral arim	inglyiolations (Sec.18	U.S.C. 1001.)
Intentional misstatemen	ts or omissions of fact constitut			